TMS
Based on 9 publication(s) in Google Scholar
TMS ((E)-2,3',4,5'-tetramethoxystilbene) is a selective and competitive CYP1B1 inhibitor with an IC50 of 6 nM and a Ki value of 3 nM. TMS shows a lesser extent inhibitory effect on CYP1A1 (IC50=300 nM) and CYP1A2 (IC50=3.1 μM). TMS is a methylated derivative of resveratrol and has anti-cancer activity.
For research use only. We do not sell to patients.
- Purity: 99.40%
- CAS No.: 24144-92-1
- Formula: C18H20O4
- Molecular Weight:300.35
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Aging Compound Library
HY-L034
-
Antioxidant Compound Library
HY-L037
-
Oxygen Sensing Compound Library
HY-L045
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Mitochondria-Targeted Compound Library
HY-L089
-
Targeted Diversity Library
HY-L099
-
Metabolic Enzyme Compound Library
HY-L146
-
Highly Selective Inhibitors Library
HY-L158
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
MCE Bioactive Compound Library
HY-L001V
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) TMS
More- Drug Resist Updat. 2024 Nov:77:101151. [Abstract]
- Redox Biol. 2025 Sep:85:103744. [Abstract]
- J Nanobiotechnology. 2026 Mar 6;24(1):345. [Abstract]
- Part Fibre Toxicol. 2022 Jun 23;19(1):43. [Abstract]
- Environ Pollut. 2024 Mar 15:345:123467. [Abstract]
- Biochem Pharmacol. 2020 Jan:171:113733. [Abstract]
- Toxicology. 2024 May:504:153774. [Abstract]
- Mol Med Rep. 2020 Jan;21(1):393-404. [Abstract]
- FASEB J. 2025 Sep 30;39(18):e71062. [Abstract]
Biological Activity
|
CYP1B1 6 nM (IC50) |
CYP1B1 3 nM (Ki) |
CYP1A1 300 nM (IC50) |
CYP1A2 3.1 μM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BC | IC50 |
5.6 μM
Compound: 5
|
Cytotoxicity against human BC cells
Cytotoxicity against human BC cells
|
[PMID: 16919455] |
| Col2 | IC50 |
0.8 μg/mL
Compound: 3,2',4',5-TMS
|
Cytotoxicity against human Col2 cells
Cytotoxicity against human Col2 cells
|
10.1039/C3MD00317E |
| KB | IC50 |
8.6 μM
Compound: 5
|
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
|
[PMID: 16919455] |
| NCI-H187 | IC50 |
8 μM
Compound: 5
|
Cytotoxicity against human NCI-H187 cells
Cytotoxicity against human NCI-H187 cells
|
[PMID: 16919455] |
TMS, an analogue of resveratrol, is considered to be a potential cancer preventive agent since it is a potent inhibitor of CYP1B1. To assess survival of MCF-7 cells exposed to 1 μM benzo[a]pyrene (BP), 1 μM BP+1 μM TMS and 1 μM BP+4 μM TMS, cells ae incubated for up to 72 h without a media change. Luminescence units from exposed cells, expressed as a percentage of luminescence units from solvent (DMSO)-treated cells at the same time intervals. In all exposure groups, cell viability remains >90% for the first 24 h, but by 72 h, cell survival drops to 60-70%[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 24144-92-1
-
Appearance Solid
-
Molecular Weight 300.35
-
Formula C18H20O4
-
Color Light yellow to yellow
-
SMILES
COC1=CC=C(/C=C/C2=CC(OC)=CC(OC)=C2)C(OC)=C1
-
Synonyms
(E)-2,3',4,5'-tetramethoxystilbene
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (9)
-
Journal Impact Factor
-
Most Recent
-
Drug Resist Updat
CYP1B1 promotes PARPi-resistance via histone H1.4 interaction and increased chromatin accessibility in ovarian cancer. [Abstract]2024 Nov:77:101151. PMID: 39395328 -
Redox Biol
Gaylussacin, a stilbene glycoside, inhibits chronic obstructive pulmonary disease in mice. [Abstract]2025 Sep:85:103744. PMID: 40614364 -
J Nanobiotechnology
Matrix micro/nano-topography drives oncogenic signaling and drug response in a 3D osteosarcoma model. [Abstract]2026 Mar 6;24(1):345. PMID: 41787498 -
Part Fibre Toxicol
Aryl hydrocarbon receptor activation-mediated vascular toxicity of ambient fine particulate matter: contribution of polycyclic aromatic hydrocarbons and osteopontin as a biomarker. [Abstract]2022 Jun 23;19(1):43. PMID: 35739584 -
Environ Pollut
AHR/cyp1b1 signaling-mediated extrinsic apoptosis contributes to 6PPDQ-induced cardiac dysfunction in zebrafish embryos. [Abstract]2024 Mar 15:345:123467. PMID: 38311157 -
Biochem Pharmacol
Overcoming Taxol-resistance in A549 cells: A comprehensive strategy of targeting P-gp transporter, AKT/ERK pathways, and cytochrome P450 enzyme CYP1B1 by 4-hydroxyemodin. [Abstract]2020 Jan:171:113733. PMID: 31783010 -
Toxicology
Metabolism-dependent mutagenicity of two structurally similar tobacco-specific nitrosamines (N-nitrosonornicotine and N-nitrosoanabasine) in human cells, partially different CYPs being activating enzymes. [Abstract]2024 May:504:153774. PMID: 38490321 -
Mol Med Rep
2020 Jan;21(1):393-404. PMID: 31746392 -
FASEB J
2025 Sep 30;39(18):e71062. PMID: 40971194
Solvent & Solubility
DMSO : ≥ 50 mg/mL (166.47 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.32 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
Cell viability is determined using the Cell Titer Glo Luminescent Cell Viability Assay. In brief, MCF-7 cells are seeded in 12-well plates (75 000 cells per well) in triplicate. Attached cells are exposed to 1 μM BP in the presence of 0, 1 or 4 μM TMS. At 4, 12, 24 or 72 h, RIPA Lysis Buffer (1x) is added to lyse the cells. A diluted sample of homogeneous cell lysate is transferred in duplicate to a 96-well plate and combined with an equivalent volume of Cell Titer Glo Luminescence. Luminescence measure using the Tropix 717 Microplate Luminometer. To examine viability of cells exposed to BP alone, the 72-h treatment is repeated twice, and for each experiment cells are assayed in triplicate. The values are expressed as % of the DMSO-alone solvent control[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice[1]
36 three-weeks-old male spontaneously hypertensive rats (SHR) and 36 age-matched WKY are used throughout this research. Each strain of rats is split into two groups; one group is injected daily with TMS (600 μg/kg) and the other with vehicle (DMSO; 100 μL) beginning at 8 weeks of age. Systolic BP and mean arterial pressure (MAP) are measured twice a week from 4 weeks of age; a noninvasive tail cuff method is used[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Sanghee Kim, et al. Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors. J Med Chem. 2002 Jan 3;45(1):160-4. [Content Brief]
[2]. Einem Lindeman T, et al. The resveratrol analogue, 2,3',4,5'-tetramethoxystilbene, does not inhibit CYP gene expression, enzyme activity and benzo[a]pyrene-DNA adduct formation in MCF-7 cells exposed to benzo[a]pyrene. Mutagenesis. 2011 Sep;26(5):629-35. [Content Brief]
[3]. Jennings BL, et al. Cytochrome P450 1B1 contributes to increased blood pressure and cardiovascular and renal dysfunction in spontaneously hypertensive rats. Cardiovasc Drugs Ther. 2014 Apr;28(2):145-61. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.3294 mL | 16.6472 mL | 33.2945 mL | 83.2362 mL |
| 5 mM | 0.6659 mL | 3.3294 mL | 6.6589 mL | 16.6472 mL | |
| 10 mM | 0.3329 mL | 1.6647 mL | 3.3294 mL | 8.3236 mL | |
| 15 mM | 0.2220 mL | 1.1098 mL | 2.2196 mL | 5.5491 mL | |
| 20 mM | 0.1665 mL | 0.8324 mL | 1.6647 mL | 4.1618 mL | |
| 25 mM | 0.1332 mL | 0.6659 mL | 1.3318 mL | 3.3294 mL | |
| 30 mM | 0.1110 mL | 0.5549 mL | 1.1098 mL | 2.7745 mL | |
| 40 mM | 0.0832 mL | 0.4162 mL | 0.8324 mL | 2.0809 mL | |
| 50 mM | 0.0666 mL | 0.3329 mL | 0.6659 mL | 1.6647 mL | |
| 60 mM | 0.0555 mL | 0.2775 mL | 0.5549 mL | 1.3873 mL | |
| 80 mM | 0.0416 mL | 0.2081 mL | 0.4162 mL | 1.0405 mL | |
| 100 mM | 0.0333 mL | 0.1665 mL | 0.3329 mL | 0.8324 mL |
TMS Related Classifications
HY-19340 Related Classifications
Powered by Bioz